Communiqués Prescient Therapeutics Limited

Actions

PTX

AU000000PTX3

Recherche biotechnologique et médicale

Marché Fermé - Australian S.E. 08:10:31 21/08/2026			Varia. 5j.	Varia. 1 janv.
0,0760 ^AUD	-1,30%		-11,63%	-9,52%

21/08	Prescient Therapeutics Limited publie ses résultats pour l'exercice clos le 30 juin 2026	CI
03/08	Transcript : Prescient Therapeutics Limited - Special Call

Communiqués

22/05/24	Prescient Therapeutics PTX-100 shows promising results in Phase 1b study	AQ
16/06/23	Prescient Therapeutics showcases cell therapy data at prestigious ISCT conference	AQ
09/03/23	Prescient Therapeutics thrilled with additional Orphan Drug Designation status for PTX-100	AQ
25/07/22	Prescient Therapeutics : June 2022 Quarterly Update and Appendix 4C	PU
22/07/22	Prescient Therapeutics : Application for quotation of securities - PTX	PU
16/06/22	Prescient Therapeutics : Application for quotation of securities - PTX	PU
29/04/22	Prescient Therapeutics : March 2022 Quarterly Update and Appendix 4C	PU
06/04/22	Prescient Therapeutics : Application for quotation of securities - PTX	PU
07/12/21	Prescient Therapeutics : Application for quotation of securities - PTX	PU
30/11/21	Prescient Therapeutics : Application for quotation of securities - PTX	PU
24/04/19	Prescient Therapeutics : March 2019 Appendix 4C - Quarterly	PU
27/03/19	Prescient Therapeutics : Notice of General Meeting/Proxy Form	PU
27/03/19	Prescient Therapeutics : Amended Appendix 3B - Rights Issue	PU
25/03/19	Prescient Therapeutics : Letter to Optionholders	PU
25/03/19	Prescient Therapeutics : Letter to Ineligible Shareholders	PU
25/03/19	Prescient Therapeutics : Letter to Eligible Shareholders	PU
25/03/19	Prescient Therapeutics : Appendix 3B - Rights Issue	PU
25/03/19	Prescient Therapeutics : Prospectus	PU
25/03/19	Prescient Therapeutics : Capital Raising Presentation - March 2019	PU
25/03/19	Prescient Therapeutics : Completes Equity Raising to Raise $9.1 Million	PU
25/02/19	Prescient Therapeutics : Investor Presentation - February 2019	PU
15/01/19	Prescient Therapeutics : Receipt of R&D Tax Rebate	PU
10/12/18	Prescient Therapeutics : Interim Durability Analysis of PTX-200 Breast Cancer Study	PU
20/11/18	Prescient Therapeutics : Results of Annual General Meeting	PU
20/11/18	Prescient Therapeutics : AGM Presentation	PU